Primary immunodeficiencies and the control of Epstein-Barr virus infection

Annals of the New York Academy of Sciences

Volumn 1356, Issue 1, 2015, Pages 22-44

  Palendira, Umaimainthan ^a,b   Rickinson, Alan B ^c  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cell mediated immunity; Epstein Barr virus; Genetic defects; Primary immunodeficiencies

Indexed keywords

ARTICLE; CANCER SUSCEPTIBILITY; CELL EXPANSION; DISEASE ASSOCIATION; EFFECTOR CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOLOGIST; IMMUNOPATHOLOGY; INFECTION CONTROL; INFECTION SENSITIVITY; LYMPHOPROLIFERATIVE DISEASE; MONONUCLEOSIS; NATURAL KILLER CELL; NONHUMAN; T LYMPHOCYTE; ANIMAL; BURKITT LYMPHOMA; CELLULAR IMMUNITY; GENETIC DISORDER; GENETICS; IMMUNOLOGY; PATHOLOGY;

ANIMALS; BURKITT LYMPHOMA; GENETIC DISEASES, INBORN; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFECTIOUS MONONUCLEOSIS; KILLER CELLS, NATURAL; T-LYMPHOCYTES;

EID: 84949096575     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12937     Document Type: Article

References (159)

1. Fischer, A. 2007. Human primary immunodeficiency diseases. Immunity 27: 835-845.
2. Casanova, J.-L. & L. Abel. 2004. The human model: a genetic dissection of immunity to infection in natural conditions. Nat. Rev. Immunol. 4: 55-66.
3. Aguilar, C. et al. 2014. Prevention of infections during primary immunodeficiency. Clin. Infect. Dis. 59: 1462-1470.
4. Longnecker, R.M., E. Kieff & J.I. Cohen. 2013. "Epstein-Barr virus." In Fields Virology. D.M. Knipe & P.M. Howley, Eds.: Vol. 2: 1898-1959. Lippincott Williams & Wilkins.
5. Young, L.S. & A.B. Rickinson. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4: 757-768.
6. Taylor, G.S., H.M. Long, J.M. Brooks, et al. 2014. The immunology of Epstein-Barr virus-induced disease. Annu. Rev. Immunol. 33: 787-821.
7. Rickinson, A.B., H.M. Long, U. Palendira, et al. 2014. Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory. Trends Immunol. 35: 159-169.
8. Thorley-Lawson, D.A. & A. Gross. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350: 1328-1337.
9. Thorley-Lawson, D.A., J.B. Hawkins, S.I. Tracy & M. Shapiro. 2013. The pathogenesis of Epstein-Barr virus persistent infection. Curr. Opin. Virol. 3: 227-232.
10. Kang, M.-S. & E. Kieff. 2015. Epstein-Barr virus latent genes. Exp. Mol. Med. 47: e131.
11. Kurth, J. et al. 2000. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 13: 485-495.
12. Thorley-Lawson, D.A. 2001. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1: 75-82.
13. Küppers, R. 2003. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol. 3: 801-812.
14. Heath, E. et al. 2012. Epstein-Barr virus infection of naïve B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology. PLoS Pathog. 8: e1002697.
15. Balfour, H.H. et al. 2013. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J. Infect. Dis. 207: 80-88.
16. Hislop, A.D., N.E. Annels, N.H. Gudgeon, et al. 2002. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195: 893-905.
17. + immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J. Exp. Med. 201: 349-360.
18. + T cell response to Epstein-Barr virus during primary and persistent infection. J. Exp. Med. 198: 903-911.
19. + T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. J. Immunol. 187: 92-101.
20. Azzi, T. et al. 2014. Role for early-differentiated natural killer cells in infectious mononucleosis. Blood 124: 2533-2543.
21. Chijioke, O. et al. 2013. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep. 5: 1489-1498.
22. Pappworth, I.Y., E.C. Wang & M. Rowe. 2007. The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing. J. Virol. 81: 474-482.
23. Chung, B.K. et al. 2013. Innate immune control of EBV-infected B cells by invariant natural killer T cells. Blood 122: 2600-2608.
24. + NKT cells suppress tumorigenesis by EBV-associated malignancies. Cancer Res. 69: 7935-7944.
25. Xiao, W. et al. 2011. EBV-induced human CD8(+) NKT cells synergize CD4(+) NKT cells suppressing EBV-associated tumors upon induction of Th1 bias. Cell. Mol. Immunol. 8: 368.
26. Xiang, Z. et al. 2014. Targeted activation of human Vγ9Vδ2-T cells controls Epstein-Barr virus-induced B cell lymphoproliferative disease. Cancer Cell 26: 565-576.
27. Végso, G., M. Hajdu & A. Sebestyén. 2011. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options. Pathol. Oncol. Res. 17: 443-454.
28. Rasche, L., M. Kapp, H. Einsele & S. Mielke. 2014. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant. 49: 163-167.
29. Rickinson, A.B. 2014. Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin. Cancer Biol. 26: 99-115.
30. Bollard, C.M., C.M. Rooney & H.E. Heslop. 2012. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat. Rev. Clin. Oncol. 9: 510-519.
31. Haque, T. et al. 2007. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131.
32. + natural killer cell subpopulations. Blood 110: 1530-1539.
33. Mavilio, D. et al. 2003. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. U. S. A. 100: 15011-15016.
34. Mavilio, D. et al. 2005. Characterization of CD56-/16+ NK cells. Proc. Natl. Acad. Sci. U. S. A. 102: 2886-2891.
35. Bhatia, K., M.S. Shiels, A. Berg & E.A. Engels. 2012 Sarcomas other than Kaposi sarcoma occurring in immunodeficiency: interpretations from a systematic literature review. Curr. Opin. Oncol. 24: 537-546.
36. Roschewski, M. & W.H. Wilson. 2012. EBV-associated lymphomas in adults. Best Pract. Res. Clin. Haematol. 25: 75-89.
37. Al-Herz, W. et al. 2014. Primary immunodeficiency diseases: an update on the classification from the International Union of immunological societies expert committee for primary immunodeficiency. Front. Immunol. 5: 1-33.
38. Booth, C. et al. 2011. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 117: 53-62.
39. Purtilo, D.T. et al. 1975. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 305: 935-941.
40. Provisor, A. et al. 1975. Acquired agammaglobulinemia after a life-threatening illness with clinical and laboratory features of infectious mononucleosis in three related male children. N. Engl. J. Med. 293: 62-65.
41. Bar, R.S. et al. 1974. Fatal infectious mononucleosis in a family. N. Engl. J. Med. 290: 363-367.
42. Tangye, S.G. 2014. XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP. J. Clin. Immunol. 34: 772-779.
43. Bottino, C. et al. 2001. NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J. Exp. Med. 194: 235-246.
44. Parolini, S. et al. 2000. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 192: 337-346.
45. Palendira, U. et al. 2011. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol. 9: e1001187.
46. + T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 116: 3249-3257.
47. Snow, A.L. et al. 2009. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J. Clin. Invest. 119: 2976-2989.
48. + T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus. J. Exp. Med. 209: 913-924.
49. Filipovich, A.H., K. Zhang, A.L. Snow & R.A. Marsh. 2010. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood 116: 3398-3408.
50. Schmid, J.P. et al. 2011. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 117: 1522-1529.
51. Rigaud, S. et al. 2006. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444: 110-114.
52. Marsh, R.A. et al. 2010. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 116: 1079-1082.
53. Obexer, P. & M.J. Ausserlechner. 2014. X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front. Oncol. 4: 1-9.
54. Stephane, G. et al. 2013. Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic propensity that is counterbalanced by XIAP. Blood 121: 614-623.
55. Lopez-granados, E. et al. 2014. A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein-Barr virus-specific T cells. Clin. Exp. Immunol. 178: 470-482.
56. Salzer, E. et al. 2013. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica 98: 473-478.
57. Van Montfrans, J.M. et al. 2012. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J. Allergy Clin. Immunol. 129: 787-793.e6.
58. Alkhairy, O.K. et al. 2015. Novel mutations in TNFRSF7/CD27: clinical, immunologic, and genetic characterization of human CD27 deficiency. J. Allergy Clin. Immunol. 136: 703-712.e10.
59. Denoeud, J. & M. Moser. 2011. Role of CD27/CD70 pathway of activation in immunity and tolerance. J. Leukoc. Biol. 89: 195-203.
60. Peperzak, V., Y. Xiao, E.A.M. Veraar & J. Borst. 2010. CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J. Clin. Invest. 120: 168-178.
61. Coquet, J.M. et al. 2013. The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity. Immunity 38: 53-65.
62. Rowe, M. et al. 1985. Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int. J. Cancer 35: 435-441.
63. Byun, M. et al. 2013. Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J. Exp. Med. 210: 1743-1759.
64. 2+ regulation of immunity against Epstein-Barr virus. Blood 123: 2148-2152.
65. 2+ revealed by human T-cell immunodeficiency. Nature 475: 471-476.
66. 2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 341: 186-191.
67. Berg, L.J., L.D. Finkelstein, J.A. Lucas & P.L. Schwartzberg. 2005. Tec family kinases in T lymphocyte development and function. Annu. Rev. Immunol. 23: 549-600.
68. Linka, R.M. et al. 2012. Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases. Leukemia 26: 963-971.
69. Stepensky, P. et al. 2011. IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica 96: 472-476.
70. Huck, K. et al. 2009. Girls homozygous for an IL-2- inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J. Clin. Invest. 119: 1350-1358.
71. + T-cell lymphopenia. Blood 124: 655-657.
72. Ghosh, S., K. Bienemann, K. Boztug & A. Borkhardt. 2014. Interleukin-2-inducible T-cell kinase (ITK) deficiency-clinical and molecular aspects. J. Clin. Immunol. 34: 892-899.
73. Pieters, J., P. Müller & R. Jayachandran. 2013. On guard: coronin proteins in innate and adaptive immunity. Nat. Rev. Immunol. 13: 510-518.
74. Shiow, L.R. et al. 2008. The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency. Nat. Immunol. 9: 1307-1315.
75. Moshous, D. & J.-P. de Villartay. 2014. The expanding spectrum of human coronin 1A deficiency. Curr. Allergy Asthma Rep. 14: 481.
76. Shiow, L.R. et al. 2009. Severe combined immunodeficiency (SCID) and attention deficit hyperactivity disorder (ADHD) associated with a coronin-1A mutation and a chromosome 16p11.2 deletion. Clin. Immunol. 131: 24-30.
77. Moshous, D. et al. 2013. Whole-exome sequencing identifies coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation. J. Allergy Clin. Immunol. 131: 1594-1603.
78. Stray-Pedersen, A. et al. 2014. Compound heterozygous CORO1A mutations in siblings with a mucocutaneous-immunodeficiency syndrome of epidermodysplasia verruciformis-HPV, molluscum contagiosum and granulomatous tuberculoid leprosy. J. Clin. Immunol. 34: 871-890.
79. Jawahar, S. et al. 1996. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin. Exp. Immunol. 103: 408-413.
80. De Vries, E. et al. 1996. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 88: 3022-3027.
81. Grier, J.T. et al. 2012. Human immunode ciency-causing mutation denes CD16 in spontaneous NK cell cytotoxicity. J. Clin. Invest. 122: 3769-3780.
82. Okkenhaug, K. & B. Vanhaesebroeck. 2003. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3: 317-330.
83. Angulo, I. et al. 2013. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 342: 866-871.
84. Lucas, C.L. et al. 2014. Dominant-activating germline mutations in the gene encoding the PI (3) K catalytic subunit p110 δ result in T cell senescence and human immunodeficiency. Nat. Immunol. 15: 88-97.
85. Lucas, C.L. et al. 2014. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J. Exp. Med. 211: 2537-2547.
86. Conley, M.E. et al. 2012. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85 subunit of PI3K. J. Exp. Med. 209: 463-470.
87. Deau, M.-C. et al. 2014. A human immunodeficiency caused by mutations in the PIK3R1 gene. J. Clin. Invest. 124: 3923-3928.
88. Nandagopal, N., A.K. Ali, A.K. Komal & S.H. Lee. 2014. The critical role of IL-15-PI3K-mTOR pathway in natural killer cell effector functions. Front. Immunol. 5: 1-12.
89. Abdollahpour, H. et al. 2012. The phenotype of human STK4 deficiency. Blood 119: 3450-3457.
90. Nehme, N.T. et al. 2012. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 119: 3458-3468.
91. Crequer, A. et al. 2012. Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. PLoS One 7: e44010.
92. Turul, T. et al. 2009. Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency. Eur. J. Pediatr. 168: 87-93.
93. Newell, A. et al. 2011. Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency. J. Allergy Clin. Immunol. 127: 517-520.
94. Martin, E. et al. 2014. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature 510: 288-292.
95. Woodbine, L., A.R. Gennery & P.A. Jeggo. 2014. Reprint of "The clinical impact of deficiency in DNA non-homologous end-joining". DNA Repair (Amst) 17: 9-20.
96. Moshous, D. et al. 2003. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J. Clin. Invest. 111: 381-387.
97. Rohr, J. et al. 2010. Chronic inflammatory bowel disease as key manifestation of atypical ARTEMIS deficiency. J. Clin. Immunol. 30: 314-320.
98. Bajin, I˙.Y. et al. 2013. Atypical combined immunodeficiency due to Artemis defect: a case presenting as hyperimmunoglobulin M syndrome and with LGLL. Mol. Immunol. 56: 354-357.
99. Enders, A. et al. 2006. A severe form of human combined immunodeficiency due to mutations in DNA ligase IV. J. Immunol. 176: 5060-5068.
100. Riballo, E. et al. 1999. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr. Biol. 9: 699-702.
101. Yue, J. et al. 2013. Identification of the DNA repair defects in a case of Dubowitz syndrome. PLoS One 8: e54389.
102. Buck, D. et al. 2006. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur. J. Immunol. 36: 224-235.
103. O'Driscoll, M. et al. 2001. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol. Cell 8: 1175-1185.
104. + severe combined immunodeficiency caused by a LIG4 mutation. J. Clin. Invest. 116: 137-145.
105. Grunebaum, E., A. Bates & C.M. Roifman. 2008. Omenn syndrome is associated with mutations in DNA ligase IV. J. Allergy Clin. Immunol. 122: 1219-1220.
106. Ben-Omran, T.I., K. Cerosaletti, P. Concannon, et al. 2005. A patient with mutations in DNA Ligase IV: clinical features and overlap with Nijmegen breakage syndrome. Am. J. Med. Genet. A 137A: 283-287.
107. Toita, N. et al. 2007. Epstein-Barr virus-associated B-cell lymphoma in a patient with DNA ligase IV (LIG4) syndrome. Am. J. Med. Genet. A 143A: 742-745.
108. Vicente, C., A. Conchillo, M.A. García-Sánchez & M.D. Odero. 2012. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit. Rev. Oncol. Hematol. 82: 1-17.
109. Mace, E.M. et al. 2013. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56 bright subset. Blood 121: 2669-2677.
110. Spinner, M.A. et al. 2014. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 123: 809-821.
111. Biron, C.A., K.S. Byron & J.L. Sullivan. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320: 1731-1735.
112. Hughes, C.R. et al. 2012. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J. Clin. Invest. 122: 814-820.
113. Gineau, L. et al. 2012. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J. Clin. Invest. 122: 821-832.
114. Dunne, J. et al. 2006. A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am. J. Hum. Genet. 78: 721-727.
115. Kaplan, J., I. De Domenico & D.M. Ward. 2008. Chediak-Higashi syndrome. Curr. Opin. Hematol. 15: 22-29.
116. Spritz, R.A. 1998. Molecular genetics of the Hermansky-Pudlak and Chediak-Higashi syndromes. Platelets 9: 21-29.
117. Roder J.C. et al. 1980. A new immunodeficiency disorder in humans involving NK cells. Nature 284: 553-555.
118. Jessen, B. et al. 2011. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. Blood 118: 4620-4629.
119. Merino, F., M. Pauza & D.T. Purtilo. 1986. Anti-Epstein-Barr virus memory T cell response in Chediak-Higashi syndrome patients. Immunol. Lett. 12: 51-54.
120. Nagai, K., F. Ochi, K. Terui, et al. 2013. Clinical characteristics and outcomes of Chediak-Higashi syndrome. A nationwide survey of Japan. Pediatr. Blood Cancer 60: 1582-1586.
121. Spritz, R.A. 1998. Genetic defects in Chediak-Higashi syndrome and the beige mouse. J. Clin. Immunol. 18: 97-105.
122. Okano, M. & T.G. Gross. 2000. A review of Epstein-Barr virus infection in patients with immunodeficiency disorders. Am. J. Med. Sci. 319: 392-396.
123. Merino, F., W. Henle & P. Ramírez-Duque. 1986. Chronic active Epstein-Barr virus infection in patients with Chediak-Higashi syndrome. J. Clin. Immunol. 6: 299-305.
124. Ogimi, C. et al. 2011. Rituximab and cyclosporine therapy for accelerated phase Chediak-Higashi syndrome. Pediatr. Blood Cancer 57: 677-680.
125. Thrasher, A.J. & S.O. Burns. 2010. WASP: a key immunological multitasker. Nat. Rev. Immunol. 10: 182-192.
126. Massaad, M.J., N. Ramesh & R.S. Geha. 2013. Wiskott-Aldrich syndrome: a comprehensive review. Ann. N. Y. Acad. Sci. 1285: 26-43.
127. Sullivan, K.E., C.A. Mullen, R.M. Blaese & J.A. Winkelstein. 1994. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J. Pediatr. 125: 876-885.
128. Gulley, M.L., C.L. Chen & N. Raab-Traub. 1993. Epstein-Barr virus-related lymphomagenesis in a child with Wiskott-Aldrich syndrome. Hematol. Oncol. 11: 139-145.
129. Yoshida, K. et al. 1997. Epstein-Barr virus-associated malignant lymphoma with macroamylasemia and monoclonal gammopathy in a patient with Wiskott-Aldrich syndrome. Pediatr. Hematol. Oncol. 14: 85-89.
130. Nakanishi, M. et al. 1993. Distinct clonotypic Epstein-Barr virus-induced fatal lymphoproliferative disorder in a patient with Wiskott-Aldrich syndrome. Cancer 72: 1376-1381.
131. Du, S. et al. 2011. Hodgkin's and non-Hodgkin's lymphomas occurring in two brothers with Wiskott-Aldrich syndrome and review of the literature. Pediatr. Dev. Pathol. 14: 64-70.
132. Sasahara, Y. et al. 2001. Epstein-Barr virus-associated Hodgkin's disease in a patient with Wiskott-Aldrich syndrome. Acta Paediatr. 90: 1348-1351.
133. Palenzuela, G., F. Bernard, Q. Gardiner & M. Mondain. 2003. Malignant B cell non-Hodgkin's lymphoma of the larynx in children with Wiskott-Aldrich syndrome. Int. J. Pediatr. Otorhinolaryngol. 67: 989-993.
134. Sebire, N.J., S. Haselden, M. Malone, et al. 2003. Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy. J. Clin. Pathol. 56: 555-557.
135. Paull, T.T. 2015. Mechanisms of ATM activation. Annu. Rev. Biochem. 84: 711-738.
136. Chopra, C. et al. 2014. Immune deficiency in ataxia-telangiectasia: a longitudinal study of 44 patients. Clin. Exp. Immunol. 176: 275-282.
137. Kulinski, J.M. & V.L. Tarakanova. 2013. Reply to "testing for herpesvirus infection is essential in children with chromosomal-instability syndromes." J. Virol. 87: 3618.
138. Suarez, F. et al. 2014. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French National Registry of Primary Immune Deficiencies. J. Clin. Oncol. 33: 202-208.
139. Price, S. et al. 2014. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 123: 1989-1999.
140. Straus, S.E. et al. 2001. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98: 194-200.
141. Pace, R. & D.C. Vinh. 2013. Autoimmune lymphoproliferative syndrome and Epstein-Barr virus-associated lymphoma: an adjunctive diagnostic role for monitoring EBV viremia? Case Reports Immunol. 2013: 245893.
142. Durandy, A., S. Kracker & A. Fischer. 2013. Primary antibody deficiencies. Nat. Rev. Immunol. 13: 519-533.
143. Faulkner, G.C. et al. 1999. X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J. Virol. 73: 1555-1564.
144. Ogembo, J.G. et al. 2013. Human complement receptor type 1/CD35 is an Epstein-Barr virus receptor. Cell Rep. 3: 371-385.
145. Conacher, M. et al. 2005. Epstein-Barr virus can establish infection in the absence of a classical memory B-cell population. J. Virol. 79: 11128-11134.
146. Qamar, N. & R.L. Fuleihan. 2014. The hyper IgM syndromes. Clin. Rev. Allergy Immunol. 46: 120-130.
147. De la Salle, H. et al. 2002. Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin. Exp. Immunol. 128: 525-531.
148. Konstantinou, P. et al. 2013. Transporter associated with antigen processing deficiency syndrome: case report of an adolescent with chronic perforated granulomatous skin lesions due to TAP2 mutation. Pediatr. Dermatol. 30: e223-e225.
149. Gadola, S.D, H.T Monis-Teisserenc, J. Trowsdale, et al. 2000. TAP deficiency syndrome. Clin. Exp. Immunol. 121: 173-178.
150. Lautscham, G. et al. 2001. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+)T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway. J. Exp. Med. 194: 1053-1068.
151. Lautscham, G., A. Rickinson & N. Blake. 2003. TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus. Microbes Infect. 5: 291-299.
152. Oliveira, C.C. & T. Van Hall. 2013. Importance of TAP-independent processing pathways. Mol. Immunol. 55: 113-116.
153. Ouederni, M. et al. 2011. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood 118: 5108-5118.
154. Hutt-Fletcher, L.M. 2007. Epstein-Barr virus entry. J. Virol. 81: 7825-7832.
155. Bax, H.I. et al. 2013. B-cell lymphoma in a patient with complete interferon gamma receptor 1 deficiency. J. Clin. Immunol. 33: 1062-1066.
156. De Beaucoudrey, L. et al. 2010. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 89: 381-402.
157. Greenspan, J.S. et al. 1985. Replication of Epstein-Barr virus within the epithelial cells of oral 'hairy' leukoplakia, an AIDS-associated lesion. N. Engl. J. Med. 313: 1564-1571.
158. + T cells in immunity to viruses. Nat. Rev. Immunol. 12: 136-148.
159. Le Borgne, M. & A.S. Shaw. 2012. SAP signaling: a dual mechanism of action. Immunity 36: 899-901.